| Company | Value | Change | %Change |
|---|
The company’s revenue also posted a strong growth of 17.7% YoY, climbing to ₹1,962.6 crore, compared to ₹1,667.6 crore in Q3FY24, reflecting sustained demand across key markets.
Operationally, Emcure’s EBITDA grew 15.5% YoY to ₹354.5 crore, from ₹306.8 crore in the year-ago quarter. However, EBITDA margin came in at 18%, slightly lower than 18.4% last year, indicating some pressure on profitability despite a steady rise in revenue.
Emcure is one of the few Indian pharmaceutical majors with no direct exposure to the US generics market, a factor that has contributed to its earnings stability.Also read: Unichem Labs Q3 Results: EBITDA more than doubles, margins expand even as profit dips
Instead, the company has focused on building a diverse and complex portfolio across India, Canada, Europe, and other emerging markets, allowing it to capture growth opportunities across multiple geographies.
Investors reacted positively to the results, with Emcure Pharmaceuticals Ltd shares rising 3.6% on Thursday to close at ₹1,294.80 on the BSE.
First Published: Feb 6, 2025 4:09 PM IS
